Antimicrobial agents have had a major impact on human health. Together with vaccines, they have contributed to reduced mortality, extended lifespan, and enhanced quality of life. Among drugs used in human medicine, however, they are distinctive in that their use promotes the occurrence of drug resistance in the pathogens they are designed to treat as well as in other “bystander” organisms. Indeed, the history of antimicrobial development has been driven in large part by the medical need engendered by the emergence of resistance to each generation of agents. Thus, the careful and appropriate use of antimicrobial drugs is particularly important not only for optimizing efficacy and minimizing adverse effects but also for minimizing the risk of resistance and preserving the value of existing agents. Although this chapter focuses on antibacterial agents, the optimal use of all antimicrobials depends on an understanding of each drug’s mechanism of action, spectrum of activity, mechanisms of resistance, pharmacology, and adverse effect profile. This information is applied in the context of the patient’s clinical presentation, underlying conditions, and epidemiology to define the site and likely nature of the infection or other condition and thus to choose the best therapy. Gathering of microbiologic information is important for refining therapeutic choices on the basis of documented pathogen and susceptibility data whenever possible; this information also makes it possible to choose more targeted therapy, thereby reducing the risk of selection of resistant bacteria. Durations of therapy are chosen according to the nature of the infection and the patient’s response to treatment and are informed by clinical studies when they are available, with the understanding that shorter courses are less likely than longer ones to promote the emergence of resistance. This chapter and the one that follows provide specific information that is necessary for making informed choices among antibacterial agents. The mechanisms of action of antibacterial agents are discussed in detail in the text of this chapter, and mechanisms of resistance are discussed in detail in Chap. 140. Both types of mechanisms are summarized for the most commonly used groups of agents in Table 139-1. A schematic of antibacterial targets is provided in Fig. 139-1.
TABLE 139-1Mechanisms of Action of and Resistance to Antibacterial Agents ||Download (.pdf) TABLE 139-1 Mechanisms of Action of and Resistance to Antibacterial Agents
|Antibacterial Agent(s) ||Major Target ||Mechanism(s) of Action ||Mechanism(s) of Resistance |
|β-Lactams (penicillins, cephalosporins, monobactams, carbapenems) ||Cell wall synthesis ||Bind cell wall cross-linking enzymes (PBPs, transpeptidases) || |
Drug inactivation by β-lactamases
Altered PBP targets
Reduced diffusion through porin channels
|Glycopeptides (vancomycin, teicoplanin, telavancin, dalbavancin, oritavancin) ||Cell wall synthesis || |
Block cell wall glycosyltransferases by binding D-Ala-D-Ala stem-peptide terminus
Teicoplanin, telavancin, dalbavancin, and oritavancin: affect membrane function
Altered D-Ala-D-Ala target (D-Ala-D-Lac)
Increased D-Ala-D-Ala target binding at sites distant from cell wall synthesis enzymes
|Bacitracin ||Cell wall synthesis ||Blocks lipid carrier of cell wall precursors ||Active drug efflux |
|Fosfomycin ||Cell wall synthesis ||Blocks linkage of stem peptide to NAG by enoyltransferase || |
Target enzyme overexpression
|Aminoglycosides (gentamicin, tobramycin, amikacin) ||Protein synthesis || |
Bind 30S ribosomal subunit
Block translocation of peptide chain
Cause misreading of mRNA
Methylation at ribosome binding site
Decreased permeation to target due to active efflux
|Tetracyclines (tetracycline, doxycycline, minocycline) ||Protein synthesis || |
Bind 30S ribosomal subunit
Inhibit peptide elongation
Active drug efflux
Ribosomal protection proteins
|Tigecycline ||Protein synthesis ||Same as tetracyclines ||Active drug efflux (pumps different from those affecting tetracyclines) |
|Macrolides (erythromycin, clarithromycin, azithromycin) and ketolide (telithromycin) ||Protein synthesis || |
Bind 50S ribosomal subunit
Block peptide chain exit
Methylation at ribosome binding site
Active drug efflux
|Lincosamides (clindamycin) ||Protein synthesis || |
Bind 50S ribosomal subunit
Block peptide bond formation
|Methylation at ribosome binding site |
|Streptogramins (quinupristin, dalfopristin) ||Protein synthesis ||Same as macrolides || |
Same as macrolides
|Chloramphenicol ||Protein synthesis || |
Binds 50S ribosomal subunit
Blocks aminoacyl tRNA positioning
|Drug-modifying enzymes |
|Oxazolidinones (linezolid, tedizolid) ||Protein synthesis || |
Bind 50S ribosomal subunit
Inhibit initiation of peptide synthesis
Altered rRNA binding site
Methylation of ribosome binding site
|Mupirocin ||Protein synthesis ||Blocks isoleucyl tRNA synthetase || |
Acquired resistant tRNA synthetase (drug bypass)
Altered native tRNA synthetase target
|Sulfonamides (sulfadiazine, sulfisoxazole, and sulfamethoxazole) ||Folate synthesis ||Inhibit dihydropteroate synthetase ||Acquired resistant dihydropteroate synthetase (drug bypass) |
|Trimethoprim ||Folate synthesis ||Inhibits DHFR ||Acquired resistant DHFR (drug bypass) |
|Quinolones (norfloxacin, ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, gemifloxacin, delafloxacin) ||DNA synthesis || |
Inhibit DNA gyrase and DNA topoisomerase IV
Enzyme–DNA–drug complex: block DNA replication apparatus
Protection of target from drug
Drug-modifying enzyme (ciprofloxacin)
|Rifamycins (rifampin, rifabutin, rifapentine) ||RNA synthesis ||Inhibit RNA polymerase ||Altered target |
|Nitrofurantoin ||Nucleic acid synthesis ||Reduces reactive drug derivatives that damage DNA ||Altered drug-activating enzymes |
|Metronidazole ||Nucleic acid synthesis ||Reduces reactive drug derivatives that damage DNA || |
Altered drug-activating enzyme
Acquired detoxifying enzymes
|Polymyxins (polymyxin B and polymyxin E [colistin]) ||Cell membrane ||Bind LPS and disrupt both outer and cytoplasmic membranes ||Altered cell membrane charge with reduced drug binding |
|Daptomycin ||Cell membrane ||Produces membrane channel and membrane leakage ||Altered cell membrane with reduced drug binding |
Antibacterial targets. A, aminoacyl site; DHFR, dihydrofolate reductase; DHPS, dihydropteroate synthetase; P, peptidyl site; PBP, penicillin-binding protein; tRNA-aa, aminoacyl tRNA.
Multiple essential components of bacterial cell structures and metabolism have been the targets of antibacterial agents used in clinical medicine, and the interaction of an agent with its target results in either inhibition of bacterial growth and replication (bacteriostatic effect) or bacterial killing (bactericidal effect). In general, targets have been chosen because they either do not exist in mammalian cells and physiology or are sufficiently different from their bacterial counterparts to allow selective bacterial targeting. Treatment with bacteriostatic agents is effective when the patient’s host defenses are sufficient to contribute to eradication of the infecting pathogen. In patients with impaired host defenses (e.g., neutropenia) or infections at body sites with impaired or limited host defenses (e.g., meningitis and endocarditis), bactericidal agents are generally preferred.
INHIBITION OF CELL WALL SYNTHESIS
The bacterial cell wall, which is external to the cytoplasmic membrane and has no counterpart in mammalian cells, protects bacterial cells from lysis under low osmotic conditions. The cell wall is a cross-linked peptidoglycan composed of a polymer of alternating units of N-acetylglucosamine (NAG) and N-acetylmuramic acid (NAM), four-amino-acid stem peptides linked to each NAM, and a peptide cross-bridge that links adjacent stem peptides to form a netlike structure. Several steps in peptidoglycan synthesis are targets of antibacterial agents. Inhibition of cell wall synthesis generally results in a bactericidal effect that is linked to cell lysis. This effect results not only from the blocking of new cell-wall formation but from the uninhibited action of cell wall–remodeling enzymes called autolysins, which cleave peptidoglycan as part of normal cell-wall growth.
In gram-positive bacteria the peptidoglycan is the most external cell structure, but in gram-negative bacteria an asymmetric lipid outer membrane is external to the peptidoglycan and contains diffusion channels called porins. The space between the cytoplasmic membrane peptidoglycan and the outer membrane is referred to as the periplasmic space. Most antibacterial drugs enter the gram-negative bacterial cell through a porin channel, since the outer membrane is a major diffusion barrier. Although the peptidoglycan layer is thicker in gram-positive (20–80 nm) than in gram-negative (1 nm) bacteria, peptidoglycan itself constitutes only a limited diffusion barrier for antibacterial agents.
The β-lactam drugs, including penicillins, cephalosporins, monobactams, and carbapenems, target transpeptidase enzymes (also called penicillin-binding proteins or PBPs) involved in the stem-peptide cross-linking step. Inhibitors of β-lactamases—enzymes that can degrade β-lactams—are used in combination with some β-lactams to expand their spectrum of activity.
Glycopeptides and Lipoglycopeptides
The glycopeptides, including vancomycin and teicoplanin, and the lipoglycopeptides, including telavancin, dalbavancin, and oritavancin, bind the two terminal D-alanine residues of the stem peptide, hindering the glycosyltransferase involved in polymerizing NAG–NAM units as well as transpeptidases. Vancomycin also binds to the lipid II intermediate that delivers cell wall precursor subunits. The additional binding of teicoplanin, telavancin, dalbavancin, and oritavancin to the bacterial cytoplasmic membrane contributes to their increased potency. Both β-lactams and glycopeptides interact with their targets external to the cytoplasmic membrane.
These agents interrupt enzymatic steps in the production of peptidoglycan precursors in the cytoplasm.
INHIBITION OF PROTEIN SYNTHESIS
Most inhibitors of bacterial protein synthesis target bacterial ribosomes, whose difference from eukaryotic ribosomes allows selective antibacterial action. Some inhibitors bind to the 30S ribosomal subunit and others to the 50S subunit. Most protein synthesis–inhibiting agents are bacteriostatic; aminoglycosides are an exception and are bactericidal.
Aminoglycosides (amikacin, gentamicin, kanamycin, netilmicin, streptomycin, and tobramycin) bind irreversibly to 16S ribosomal RNA (rRNA) of the 30S ribosomal subunit, blocking the translocation of peptidyl transfer RNA (tRNA) from the A (aminoacyl) to the P (peptidyl) site and, at low concentrations, causing misreading of messenger RNA (mRNA) codons and thus causing the introduction of incorrect amino acids into the peptide chain; at higher concentrations, translocation of the peptide chain is blocked. Cellular uptake of aminoglycosides is dependent on the electrochemical gradient across the bacterial membrane. Under anaerobic conditions, this gradient is reduced, with a consequent reduction in the uptake and activity of the aminoglycosides. Spectinomycin is a related aminocyclitol antibiotic that also binds to 16S rRNA of the 30S ribosomal subunit but at a different site. This drug inhibits translocation of the growing peptide chain but does not trigger codon misreading and produces only a bacteriostatic effect.
Tetracyclines and Glycylcyclines
Tetracyclines (doxycycline, minocycline, and tetracycline) bind reversibly to the 16S rRNA of the 30S ribosomal subunit and block the binding of aminoacyl tRNA to the ribosomal A site, thereby inhibiting peptide elongation. Active transport of tetracyclines into bacterial but not mammalian cells contributes to the selectivity of these agents. Tigecycline, a derivative of minocycline and the only available glycylcycline, acts similarly to the tetracyclines but is distinctive for its ability to circumvent the most common mechanisms of resistance to the tetracyclines.
In contrast to the aminoglycosides and tetracyclines, the macrolides (azithromycin, clarithromycin, and erythromycin) and ketolides (telithromycin) bind to the 23S rRNA of the 50S ribosomal subunit. These agents block translocation of the growing peptide chain by binding to the tunnel from which the chain exits the ribosome.
Clindamycin is the only lincosamide in clinical use. It binds to the 23S rRNA of the 50S ribosomal subunit, interacting with both the ribosomal A and P sites and blocking peptide bond formation.
The only streptogramin in clinical use is a combination of quinupristin, a group B streptogramin, and dalfopristin, a group A streptogramin. Both components bind to 23S rRNA of the 50S ribosome: dalfopristin binds to both the A and P sites of the peptidyl transferase center, and quinupristin binds to a site that overlaps the macrolide-binding site, blocking the emergence of nascent peptide from the ribosome. The combination is bactericidal, but macrolide-resistant bacteria exhibit cross-resistance to quinupristin, and the remaining activity of dalfopristin alone is only bacteriostatic.
Chloramphenicol binds reversibly to the 23S rRNA of the 50S subunit in a manner that interferes with the proper positioning of the aminoacyl component of tRNA in the A site. This site of binding is near those of the macrolides and lincosamides.
Linezolid and tedizolid are the only oxazolidinones in clinical use. They bind directly to the A site in the 23S rRNA of the 50S ribosomal subunit and block binding of aminoacyl tRNA, inhibiting the initiation of protein synthesis.
Mupirocin (pseudomonic acid) is used topically. It competes with isoleucine for binding to isoleucyl tRNA synthetase, depleting stores of isoleucyl tRNA and thereby inhibiting protein synthesis.
INHIBITION OF BACTERIAL METABOLISM
Available inhibitors (antimetabolites) target the pathway for synthesis of folate, which is a cofactor in a number of one-carbon transfer reactions involved in the synthesis of some nucleic acids, including the pyrimidine thymidine and all purines (adenine and guanine), as well as some amino acids (methionine and serine) and acetyl coenzyme A. Two sequential steps in folate synthesis are targeted. The selective antibacterial effect stems from the inability of mammalian cells to synthesize folate; they depend instead on exogenous sources. Antibacterial activity, however, may be reduced in the presence of high exogenous concentrations of the end products of the folate pathway (e.g., thymidine and purines) that may occur in some infections, resulting from local breakdown of leukocytes and host tissues.
Sulfonamides, including sulfadiazine, sulfisoxazole, and sulfamethoxazole, inhibit dihydropteroate synthetase (DHPS), which adds p-aminobenzoic acid (PABA) to pteridine, producing dihydropteroate. Sulfonamides are structural analogues of PABA and act as competing enzyme substrates.
Subsequent steps in folate synthesis are catalyzed by dihydrofolate synthase, which adds glutamate to dihydropteroate, and dihydrofolate reductase (DHFR), which then generates the final product, tetrahydrofolate. Trimethoprim is a structural analogue of pteridine and inhibits DHFR. Trimethoprim is available alone but is most often used in combination products that also contain sulfamethoxazole and thus block two sequential steps in folate synthesis.
INHIBITION OF DNA AND RNA SYNTHESIS OR ACTIVITY
A variety of antibacterial agents act on these processes.
The quinolones include nalidixic acid, the first agent in the class, and newer, more widely used fluorinated derivatives (fluoroquinolones), including norfloxacin, ciprofloxacin, levofloxacin, moxifloxacin, gemifloxacin, and delafloxacin. The quinolones are synthetic compounds that inhibit bacterial DNA synthesis by interacting with the DNA complexes of two essential enzymes, DNA gyrase and DNA topoisomerase IV, which alter DNA topology. Quinolones trap enzyme–DNA complexes in such a way that they block movement of the DNA replication apparatus and can generate lethal double-strand breaks in DNA, resulting in bactericidal activity. Although mammalian cells also have type II DNA topoisomerases related to gyrase and topoisomerase IV, the structures of the mammalian enzymes are sufficiently different from those of the bacterial enzymes that quinolones have substantially selective antibacterial activity.
Rifampin, rifabutin, and rifapentine are semisynthetic derivatives of rifamycin B and bind the β subunit of bacterial RNA polymerase, thereby blocking elongation of mRNA. Their action is highly selective for the bacterial enzyme over mammalian RNA polymerases.
The reduction of nitrofurantoin, a nitrofuran compound, by bacterial enzymes produces highly reactive derivatives that are thought to cause DNA strand breakage. Nitrofurantoin is used only for the treatment of lower urinary tract infections.
Metronidazole is a synthetic nitroimidazole with activity limited to anaerobic bacteria and certain anaerobic protozoa. Reduction of its nitro group by the electron-transport system in anaerobic bacteria produces reactive intermediates that damage DNA and result in bactericidal activity. Both nitrofurantoin and metronidazole have selective antibacterial activity because the reducing activity needed to produce active derivatives is generated only by bacterial and not mammalian enzymes.
DISRUPTION OF MEMBRANE INTEGRITY
The integrity of the bacterial cytoplasmic membrane—and, in gram-negative bacteria, the outer membrane—is important for bacterial viability. Two bactericidal drugs have membrane targets.
The polymyxins, including polymyxin B and polymyxin E (colistin), are cationic cyclic polypeptides that disrupt the cytoplasmic membrane and the outer membrane (the latter by binding lipopolysaccharide, which is negatively charged).
Daptomycin is a lipopeptide that binds the cytoplasmic membrane of gram-positive bacteria in the presence of calcium, generating a channel that leads to leakage of cytoplasmic potassium ions and membrane depolarization.
PHARMACOKINETICS AND PHARMACODYNAMICS
The term pharmacokinetics describes the disposition of a drug in the body, whereas pharmacodynamics describes the determinants of drug action on the pathogen in relation to pharmacokinetic factors. An understanding of the principles governing these two areas is required for effective drug selection and dosing and for prevention of toxicities.
The process of drug disposition has four principal phases: absorption, distribution, metabolism, and excretion. These components determine the time course of drug concentrations in serum and subsequently the concentrations in other tissues and body fluids.
When a drug is given by a particular route, absorption is defined as the percentage of the dose that reaches the systemic circulation. For example, since IV administration provides direct access to the systemic circulation, 100% of a drug dose given IV is usually absorbed. The level of absorption becomes more relevant when non-IV routes are used—e.g., the oral, IM, SC, and topical routes. The percentage of a drug that is absorbed is termed its bioavailability. Examples of antibacterial agents with a high oral bioavailability include metronidazole, levofloxacin, and linezolid. IV administration and oral dosing for highly bioavailable agents usually give equivalent results. Many factors can affect a drug’s oral bioavailability, including the timing of food consumption relative to drug administration, drug-metabolizing enzymes, efflux transporters, concentration-dependent solubility, and acid degradation. Underlying conditions such as diarrhea or ileus can also affect the site of drug absorption and thereby alter bioavailability. Certain orally administered drugs have lower bioavailability because of the first-pass effect—the process by which drugs are absorbed in the small intestine through the portal circulation and then directly transported to the liver for metabolism.
Distribution describes the process by which a drug transfers reversibly between the general circulation and the tissues. After absorption into the general circulation and the central compartment (the extensively perfused organs), the drug will also distribute into the peripheral compartment (less well-perfused tissues). The volume of distribution (Vd) is a pharmacokinetic parameter that describes the amount of drug in the body at a given time relative to the measured serum concentration. Properties such as the drug’s lipophilicity, partition coefficient within different body tissues, and protein binding; blood flow; and pH can affect the Vd. Drugs with a small Vd are limited to certain areas within the body (typically extracellular fluid), whereas those with a higher Vd penetrate extensively into tissues throughout the body. Antibacterial drugs can bind to serum proteins, and a given drug is usually described as either poorly or highly protein bound. Only the unbound (free) drug is active and available to exert antibacterial effects. For example, because tigecycline is highly protein bound and also has a large Vd, concentrations of free drug in the serum are low.
Metabolism is the chemical transformation of a drug by the body. This modification can occur within several areas; the liver is the organ most commonly involved. Drugs are metabolized by enzymes, but enzyme systems have a finite capacity to metabolize a substrate drug. If a drug is given in a dose at which the concentration does not exceed the rate of metabolism, then the metabolic process is generally linear. If the dose exceeds the amount that can be metabolized, drug accumulation and potential toxicity may occur. Drugs are metabolized through phase I or phase II reactions. In phase I reactions, the drug is made more polar through dealkylation, hydroxylation, oxidation, and deamination. Polarity facilitates drug removal from the body. Phase II reactions, which include glucuronidation, sulfation, and acetylation, result in compounds larger and more polar than the parent drug. Both phases usually inactivate the parent drug, but some drugs are rendered more active. The cytochrome P450 (CYP) enzyme system is responsible for phase I reactions and is generally found in the liver. CYP3A4 is a common subfamily within this system that is responsible for the majority of drug metabolism. Antibacterial drugs can be substrates, inhibitors, or inducers of a particular CYP enzyme. Inducers, such as rifampin, can increase the production of CYP enzymes and consequently increase the metabolism of other drugs. Inhibitors, such as quinupristin-dalfopristin, cause a decrease in enzyme activity (or competition for CYP substrate) and therefore an increase in the concentration of the interacting drug.
Excretion describes the body’s mechanisms of drug elimination. Drugs can be eliminated through more than one mechanism. Renal clearance is the most common route and includes elimination through glomerular filtration, tubular secretion, and/or passive diffusion. Some agents have nonrenal clearance and rely on the biliary tree or the intestine for excretion. Excretion affects the half-life of a drug—i.e., the time it takes for the blood concentration of a drug to decrease by one-half. This value can range from minutes to days. Approximately five to seven half-lives are required for a drug to reach steady state when multiple doses are given in a time frame shorter than the half-life itself. Drug half-life and overall clearance can be extended if the organ responsible for clearance is impaired. Patients with renal or hepatic impairment may require dose adjustments that take delayed clearance into account and prevent toxicities from drug accumulation. For example, imipenem is cleared predominantly through glomerular filtration, and in the presence of renal impairment the dosing interval is typically increased to account for the increased half-life.
The term pharmacodynamics describes the relationship between the serum concentrations that determine the efficacy of the drug and the serum concentrations that produce the toxic effects of the drug. For an antibacterial agent, the pharmacodynamic focus is the type of drug exposure needed for optimal antibacterial effect in relation to the minimal inhibitory concentration (MIC)—the lowest drug concentration that inhibits the growth of a microorganism under standardized laboratory conditions. Antibacterial effect usually correlates with one of the following parameters: (1) ratio of peak serum concentration to the MIC (Cmax/MIC), (2) ratio of the area under the concentration–time curve to the MIC (AUC/MIC), or (3) duration of concentrations above the MIC (T > MIC) (Fig. 139-2).
Pharmacokinetic and pharmacodynamic model predicting efficacy of antibacterial drugs. AUC, area under the time–concentration curve; Cmax, peak serum concentration of drug; MIC, minimal inhibitory concentration; T > MIC, duration of drug concentrations above the MIC.
For concentration-dependent killing agents, as the designation implies, the higher the drug concentration, the higher the rate and extent of bacterial killing. Aminoglycosides fit into the Cmax/MIC model of pharmacodynamics activity, and a particular peak serum concentration is often targeted to achieve optimal killing. Fluoroquinolones exemplify antibacterial agents for which the AUC/MIC is a predictor of efficacy. For example, studies have found that an AUC/MIC ratio of >30 will maximize killing of S. pneumoniae by fluoroquinolones. In contrast, time-dependent killing agents reach a ceiling at which higher concentrations do not result in increased effect. Instead, these agents are active against bacteria only when the drug concentration is above the MIC. The T > MIC predicts clinical efficacy for all β-lactams. The longer the concentration of the β-lactam remains above the MIC for an infecting pathogen during the dosing interval, the greater the killing effect. For some drug classes, such as aminoglycosides, a postantibiotic effect—the delayed regrowth of surviving bacteria after exposure to an antibiotic—supports less frequent dosing.
The approach to antibiotic therapy is driven by host factors, site of infection, and local resistance profiles of suspected or known pathogens. Further, national and local drug shortages and formulary restrictions can affect available therapies. Regular monitoring of the patient and collection of laboratory data should be undertaken to streamline antibacterial therapy as appropriate and to investigate the possibility of treatment failure if the patient fails to respond appropriately.
EMPIRICAL AND DIRECTED THERAPY
Therapy is considered empirical when the causative agent has yet to be determined and therapeutic decisions are based on the severity of illness, the clinician’s assessment of likely pathogens in light of the clinical syndrome, the patient’s medical conditions and prior therapy, and relevant epidemiologic factors. For patients with severe illness, empirical therapy often takes the form of an antibacterial combination that provides broad coverage of diverse agents and thus ensures adequate treatment of possible pathogens while additional data are being collected. Directed therapy is predicated on identification of the pathogen, determination of its susceptibility profile, and establishment of the extent of the infection. Directed therapy generally allows the use of more targeted and narrower-spectrum antibacterial agents than does empirical therapy.
Information on epidemiology, exposures, and local antibacterial susceptibility patterns can help guide empirical therapy. When empirical treatment is clinically appropriate, care should be taken to obtain clinical specimens for microbiologic analysis before the initiation of therapy and to de-escalate therapy as new information is obtained about the patient’s clinical condition and the causal pathogens. De-escalation to the point of directed therapy can limit unnecessary risks to the patient as well as the risk of emergence of antibacterial resistance.
The site of infection is a consideration in antibacterial therapy, largely because of the differing abilities of drugs to penetrate and achieve adequate concentrations at particular body sites. For example, to be effective in the treatment of meningitis, an agent must (1) be able to cross the blood–brain barrier and reach adequate concentrations in the cerebrospinal fluid (CSF) and (2) be active against the relevant pathogen(s). Dexamethasone, administered with or 15–20 min before the first dose of an antibacterial drug, has been shown to improve outcomes in patients with some types of acute bacterial meningitis, but its use may reduce penetration of some antibacterial agents, such as vancomycin, into the CSF. In this case, rifampin is added because its penetration is not reduced by dexamethasone. Infections at other sites where either pathogens are protected from normal host defenses or penetration of an antibacterial drug is suboptimal include osteomyelitis, prostatitis, intraocular infections, and abscesses. In such cases, consideration must be given to the mechanism of drug delivery (e.g., intravitreal injections) as well as to the role of interventions to drain, debride, or otherwise reduce the barriers to effective antibacterial therapy.
Host factors, including immune function, pregnancy, allergies, age, renal and hepatic function, drug–drug interactions, comorbid conditions, and occupational or social exposures, should be considered.
Patients with deficits in immune function that blunt the response to bacterial infection, including neutropenia, deficient humoral immunity, and asplenia (either surgical or functional), are all at increased risk of severe bacterial infection. Such patients should be treated aggressively and often broadly in the early stages of suspected infection pending results of microbiologic tests. For asplenic patients, treatment should include coverage of encapsulated organisms, particularly Streptococcus pneumoniae, that may cause rapidly life-threatening infection.
Pregnancy affects decisions regarding antibacterial therapy in two respects. First, pregnancy is associated with an increased risk of particular infections (e.g., those caused by Listeria). Second, the potential risks to the fetus that are posed by specific drugs must be considered. As for other drugs, the safety of the vast majority of antibacterial agents in pregnancy has not been established, and such agents are grouped in categories B and C by the U.S. Food and Drug Administration. Drugs in categories D and X are contraindicated in pregnancy or lactation due to established risks. The risks associated with antibacterial use in pregnancy and during lactation are summarized in Table 139-2.
TABLE 139-2Risks Associated with Use of Antibacterial Drugs in Pregnancy and Lactation ||Download (.pdf) TABLE 139-2 Risks Associated with Use of Antibacterial Drugs in Pregnancy and Lactation
|Pregnancy Categorya ||Antibacterial Drug ||Fetal Risk Recommendationb ||Breast-Feeding Risk Recommendationb |
|B ||Azithromycin ||Limited human data. Animal data suggest low risk. ||Limited human data; probably compatible |
|Cephalosporins (including cephalexin, cefuroxime, cefixime, cefpodoxime, cefotaxime, ceftriaxone) ||Compatible ||Compatible |
|Ceftazidime-avibactam ||No human data; no fetal harm in animal studies ||Ceftazidime is excreted into human milk in low concentrations. Avibactam is excreted into the milk of lactating rats; no human studies have been conducted. |
|Ceftolozane-tazobactam ||Compatible ||Unknown |
|Clindamycin ||Compatible ||Compatible |
|Ertapenem ||No human data; probably compatible ||Limited human data; probably compatible |
|Erythromycin ||Compatible (except for estolate salt) ||Compatible |
|Meropenem and meropenem-vaborbactam ||No human data. Animal data suggest low risk. ||No human data; probably compatible |
|Metronidazole ||Human data suggest low risk. ||Interrupt breast-feeding for 12–24 h after single 2-g dose. Limited human data; potential toxicity in divided doses |
|Nitrofurantoin ||Human data suggest risk in third trimester. ||Limited human data; probably compatible. Higher risk associated with younger infants and those with G6PD deficiency |
|Penicillins (including amoxicillin, ampicillin, cloxacillin) ||Compatible ||Compatible |
|Quinupristin-dalfopristin ||Compatible. Maternal benefit must far outweigh risk to embryo/fetus. ||No human data; potential toxicity |
|Vancomycin ||Compatible ||Limited human data; probably compatible |
|C ||Chloramphenicol ||Compatible ||Limited human data; potential toxicity |
|Fluoroquinolones ||Human data suggest low risk. ||Limited human data; probably compatible |
|Clarithromycin ||Limited human data. Animal data suggest high risk. ||No human data; probably compatible |
|Imipenem-cilastatin ||Limited human data. Animal data suggest low risk. ||Limited human data; probably compatible |
|Linezolid ||Compatible. Maternal benefit must far outweigh risk to embryo/fetus. ||No human data; potential toxicity |
|Telavancin ||No human data. Animal studies have revealed evidence of teratogenicity.c ||No human data. Animal studies have revealed evidence of teratogenicity.c |
|Tedizolid ||Limited data. Embryo-fetal studies in mice, rats, and rabbits have demonstrated fetal developmental toxicities. Use only if benefit outweighs risk. ||Excreted in the breast milk of rats; unknown in humans; caution use |
|Dalbavancin ||Limited human data. At high doses in animal studies, delayed fetal maturation, increased embryo and offspring death. Use only if benefit outweighs risk. ||Excreted in the breast milk of animals; unknown in humans; caution use |
|Oritavancin ||Limited human data. Studies in rats and rabbits demonstrated no harm at 25% of recommended human dose. Use only if benefit outweighs risk. ||Excreted in the breast milk of rats; unknown in humans; caution use |
|C/D ||Amikacin ||Human data suggest low risk. ||Compatible |
|Gentamicin ||Human data suggest low risk. ||Compatible |
|D ||Kanamycin ||Human data suggest risk. ||Limited human data; probably compatible |
|Streptomycin ||Human data suggest risk. ||Compatible |
|Sulfonamides ||Human data suggest risk in third trimester. ||Limited human data; potential toxicity. Avoid in ill, stressed, premature infants and in infants with hyperbilirubinemia or G6PD deficiency. |
|Tetracyclines ||Contraindicated in second and third trimesters ||Compatible |
|Tigecycline ||Human data suggest risk in second and third trimesters. ||No human data; potential toxicity |
Allergies to antibiotics are among the most common allergies reported, and an allergy history should be obtained whenever possible before therapy is chosen. A detailed allergy history can shed light on the type of reaction experienced previously and on whether rechallenge with the same or a related medication is advisable (and, if so, under what circumstances). Allergies to the penicillins are most common. Although as many as 10% of patients may report an allergy to penicillin, studies suggest that more than 90% of these patients could tolerate a penicillin or cephalosporin. Adverse effects (Table 139-3) should be distinguished from true allergies to ensure appropriate selection of antibacterial therapy.
TABLE 139-3Common Adverse Reactions to Antibacterial Agents ||Download (.pdf) TABLE 139-3 Common Adverse Reactions to Antibacterial Agents
|Antibacterial(s) ||Potential Adverse Effects ||Comments |
|β-Lactams ||Hypersensitivity reactions ||Ranges from rash to anaphylaxis. Cross-reactivity among β-lactams is related to chemical structure and side chain similarity. |
|Neurotoxicity ||More commonly described with cefepime and imipenem, but likely a class effect. Risk is increased in patients with history of seizures, renal impairment, and advanced age. |
|Neutropenia/hematologic reactions ||May be related to high doses and prolonged duration |
|Vancomycin ||Nephrotoxicity ||Risk increases with vancomycin trough levels >20 μg/mL or concomitant administration with other potentially nephrotoxic agents. The effect is usually reversible. |
|“Red man syndrome” ||Can be managed with a slower vancomycin infusion and pretreatment with antihistamine |
|Telavancin ||QT prolongation || |
|Interference with coagulation tests ||May falsely affect INR, PT, aPTT. Perform these tests before the next dose of telavancin (when serum drug levels are at their nadir). |
|Taste disturbances || |
|Nephrotoxicity || |
|Oritavancin ||Interference with coagulation tests ||May falsely affect INR, PT, aPTT. Perform these tests at least 24 h after the dose is administered. |
|Gastrointestinal distress || |
|Dalbavancin ||Gastrointestinal distress || |
|Daptomycin ||Myopathy ||Monitor CPK levels during therapy. Rhabdomyolysis has been reported but appears to be rare. |
|Eosinophilic pneumonia || |
|Aminoglycosides ||Nephrotoxicity ||Associated with prolonged use; usually reversible |
|Ototoxicity ||Can cause both vestibular and cochlear toxicity. Ototoxicity may be irreversible. |
|Fluoroquinolones ||QTc prolongation ||Moxifloxacin appears more likely than other quinolones to exert this effect. Risk of arrhythmia increases when these drugs are given concomitantly with other QTc-prolonging agents. |
|Tendinitis ||Risk is greater among the elderly and patients receiving steroids. |
|Dysglycemia || |
|Exacerbation of myasthenia gravis || |
|Rifampin ||Hepatotoxicity ||Risk is greater when drug is given with other antituberculosis agents. When rifampin is given alone, LFT values may be transiently elevated without symptoms. |
|Orange discoloration of body fluids || |
|Tetracyclines and glycylcyclines ||Photosensitivity || |
|Gastrointestinal distress ||High incidence of diarrhea, nausea, vomiting |
|Macrolides ||Gastrointestinal distress ||Erythromycin is occasionally used as a therapeutic agent for some gastric motility disorders. |
|QTc prolongation ||Azithromycin use is associated with an increased risk of death from cardiovascular causes among patients at high baseline risk. |
|Metronidazole ||Peripheral neuropathy ||Associated with prolonged use |
|Clindamycin ||Diarrhea and pseudomembranous colitis || |
|Linezolid, tedizolid ||Myelosuppression ||Associated with prolonged use |
|Optic and peripheral neuropathy ||Associated with prolonged use |
|Lactic acidosis || |
|TMP-SMX ||Hypersensitivity reactions ||Allergy usually associated with sulfonamide moiety |
|Nephrotoxicity ||Associated with high doses |
|Hematologic effects ||Associated with prolonged use |
|Nitrofurantoin ||Pneumonitis and other pulmonary reactions ||Associated with prolonged use |
|Peripheral neuropathy ||Associated with accumulation of nitrofurantoin in renal failure. Avoid use in renal impairment. |
|Fosfomycin ||Gastrointestinal effects || |
|Polymyxins ||Nephrotoxicity ||Associated with high dose |
|Neurotoxicity ||Neuromuscular blockade and muscle weakness are well described and usually reversible. |
|Quinupristin-dalfopristin ||Arthralgias and myalgias || |
|Chloramphenicol ||Bone marrow suppression ||Aplastic anemia or hematopoietic toxicity |
Patients commonly receive other drugs that may interact with antibacterial agents. A summary of the most common drug–drug interactions, by antibacterial class, is provided in Table 139-4.
TABLE 139-4Significant Antibacterial Drug Interactions ||Download (.pdf) TABLE 139-4 Significant Antibacterial Drug Interactions
|Antibacterial(s) ||Interacting Agent(s) ||Potential Effect and Management |
|Nafcillin ||Warfarin, cyclosporine, tacrolimus ||Decreased levels of warfarin, cyclosporine via CYP3A4 induction. Monitor levels of affected drug closely if drugs are given concomitantly. |
|Ceftriaxone ||Calcium-containing IV solutions || |
Concomitant use is contraindicated in neonates (<28 days); the combination can lead to precipitation of ceftriaxone-calcium particulate.
Ceftriaxone and calcium-containing solutions can be given to infants >28 days of age provided they are given sequentially and the lines are thoroughly flushed between infusions.
|Carbapenems ||Valproic acid ||Decreased levels of valproic acid. Monitor valproic acid levels closely if drugs are given concomitantly. |
|Linezolid, tedizolid ||Serotonergic and adrenergic agents (e.g., SSRIs, vasopressors) ||Increased levels of serotonergic and adrenergic agents. Monitor for serotonin syndrome. Tedizolid may have less potential than linezolid to cause this drug interaction. |
|Quinupristin-dalfopristin ||Substrates of CYP3A4 (e.g., warfarin, ritonavir, cyclosporine, diazepam, verapamil) ||Can result in increased levels of interacting drug |
|Fluoroquinolones ||Theophyllinea ||Can result in theophylline toxicity |
|Sucralfate; antacids containing aluminum, calcium, or magnesium; ferrous sulfate– and zinc-containing multivitamins ||Can result in subtherapeutic fluoroquinolone levels. Administer fluoroquinolone 2 h before or 6 h after interacting drug. |
|Tizanidinea ||Can result in increased levels of tizanidine and hypotensive, sedative effects. Monitor for side effects if drugs are given concomitantly. |
|Rifampin ||Substrates of CYP3A4 (e.g., warfarin, ritonavir, cyclosporine, diazepam, verapamil, protease inhibitors, voriconazole) ||Can result in decreased levels of interacting drug. Avoid concomitant use if possible. If giving drugs concomitantly, monitor drug levels if possible. |
|Substrates of CYP2C19 (e.g., omeprazole, lansoprazole) || |
|Substrates of CYP2C9 (e.g., warfarin, tolbutamide) || |
|Substrates of CYP2C8 (e.g., repaglinide, rosiglitazone) || |
|Substrates of CYP2B6 (e.g., efavirenz) || |
|Hormone therapy (e.g., norethindrone) ||Can result in decreased levels of hormone. If oral contraceptive and rifampin are given concomitantly, use alternative form of birth control. |
|Tetracyclines ||Antacids or drugs containing calcium, magnesium, iron, or aluminum ||Can result in decreased absorption of tetracyclines. Administer tetracycline 2 h before or 6 h after interacting drug. |
|Warfarin ||Increased effect of warfarin. Monitor levels closely if drugs are given concomitantly. |
|Macrolidesb ||Substrates of CYP3A4 (e.g., warfarin, ritonavir, cyclosporine, diazepam, verapamil) ||Avoid concomitant administration if possible. |
|QTc-prolonging agents (e.g., fluoroquinolones, sotalol) ||Increased risk of cardiotoxicity and arrhythmias. Monitor QTc. |
|Protease inhibitors (e.g., ritonavir) ||Can result in increased levels of both macrolides and protease inhibitors. Avoid concomitant use if possible. |
|Cimetidine ||Cimetidine can increase levels of macrolides. |
|Metronidazole ||Ethanol ||Can result in disulfiram-like reaction. Ethanol may be present in some formulations of oral drug suspensions (e.g., ritonavir). |
|Warfarin ||Can increase warfarin levels. Monitor INR closely if drugs are given concomitantly. |
|TMP-SMX ||Warfarin ||Increased effect of warfarin. Monitor levels closely if drugs are given concomitantly. |
|Phenytoin ||Increased levels of phenytoin. Monitor levels closely if drugs are given concomitantly. |
|Methotrexate ||Increased levels of methotrexate. Monitor levels closely if drugs are given concomitantly. |
|Oritavancin || |
Substrates of CYP3A4 (e.g., cyclosporine, warfarin) and CYP2D6 (e.g., aripiprazole)
Substrates of CYP2C19 (e.g., omeprazole) and CYP2C9 (e.g., warfarin)
|Can result in decreased levels of interacting drug. Avoid concomitant use if possible. If giving drugs concomitantly, monitor drug levels if possible. |
Exposures, both occupational and social, may provide clues to likely pathogens. When relevant, inquiries about exposure to ill contacts, animals, insects, and water should be included in the history, along with sites of residence and travel.
Age, renal and hepatic function, and comorbid conditions are all considerations in the choice of and schedule for therapy. Dose adjustments should be made accordingly. In patients with decreased or unreliable oral absorption, IV therapy may be preferred to ensure adequate blood levels of drug and delivery of the antibacterial agent to the site of infection.
Whether empirical or directed, the duration of therapy should be determined in most clinical situations. Guidelines that synthesize available literature and expert opinion provide recommendations on therapy duration that are based on infecting organism, organ system, and patient factors. For example, the American Heart Association has published guidelines endorsed by the Infectious Diseases Society of America (IDSA) on diagnosis, antibacterial therapy, and management of complications of infective endocarditis. Similar guidelines from the IDSA exist for bacterial meningitis, urinary tract infections (including those that are catheter-associated), intraabdominal infections, community- and hospital-acquired pneumonia, skin and soft tissue infections, and other infections.
If a patient does not respond to therapy, investigations often should include the collection of additional specimens for microbiologic testing and imaging as indicated. Failure to respond can be the result of an antibacterial regimen that does not address the underlying causative organism, the development of resistance during therapy, or the existence of a focus of infection at a site poorly penetrated by systemic therapy. Some infections may also require surgical interventions (e.g., large abscesses, myonecrosis). Fever due to allergic drug reactions can sometimes complicate assessment of the patient’s response to antibacterial treatment.
Selected websites with the most up-to-date information and guidance for the clinician include the following:
CLINICAL USE OF ANTIBACTERIAL AGENTS
The clinical application of antibacterial therapy is guided by the spectrum of the agent and the suspected or known target pathogen. Infections for which specific antibacterial agents are among the drugs of choice are listed, along with associated pathogens and susceptibility data, in Table 139-5. Resistance rates of specific organisms are dynamic and should be taken into account in the approach to antibacterial therapy. While national resistance rates can serve as a reference, the most useful reference for the clinician is the most recent local laboratory antibiogram, which provides details on local resistance patterns, often on an annual or semiannual basis.
TABLE 139-5Drug Indications for Specific Infections, Associated Pathogens, and Sample Susceptibility Rates ||Download (.pdf) TABLE 139-5 Drug Indications for Specific Infections, Associated Pathogens, and Sample Susceptibility Rates
|Antimicrobial(s) ||Infections ||Common Pathogens (% Susceptible); Resistance as Noteda |
|Penicillin G ||Syphilis; yaws; leptospirosis; streptococcal infections; pneumococcal infections; actinomycosis; oral and periodontal infections; meningococcal meningitis and meningococcemia; viridans streptococcal endocarditis; clostridial myonecrosis; tetanus; rat-bite fever; Pasteurella multocida infections; erysipeloid (Erysipelothrix rhusiopathiae) ||Neisseria meningitidis; viridans streptococci (69%); Streptococcus pneumoniae (96% nonmeningitis; 68% meningitis) |
|Ampicillin, amoxicillin ||Salmonellosis; acute otitis media; Haemophilus influenzae meningitis and epiglottitis; Listeria monocytogenes meningitis; Enterococcus faecalis UTI ||Escherichia coli (51%); H. influenzae (70%); Salmonella spp. (85%) |
|Nafcillin, oxacillin ||MSSA bacteremia and endocarditis ||Staphylococcus aureus (72%); coagulase-negative staphylococci (49%) |
|Piperacillin-tazobactam ||Intraabdominal infections (facultative enteric gram-negative bacilli and obligate anaerobes); infections caused by mixed flora (aspiration pneumonia, diabetic foot ulcers); infections caused by Pseudomonas aeruginosa ||P. aeruginosa (88%)b |
|Cefazolin ||E. coli UTI; surgical prophylaxis; MSSA bacteremia and endocarditis ||E. coli (82%) |
|Cefoxitin, cefotetan ||Intraabdominal infections and pelvic inflammatory disease ||Bacteroides fragilis (60%)c |
|Ceftriaxone ||Gonococcal infections; pneumococcal meningitis; viridans streptococcal endocarditis; salmonellosis and typhoid fever; hospital-acquired infections caused by nonpseudomonal facultative gram-negative enteric bacilli ||S. pneumoniae (93%);d E. coli (91%); Klebsiella pneumoniae (89%) |
|Ceftazidime, cefepime ||Hospital-acquired infections caused by facultative gram-negative bacilli and Pseudomonas spp. ||P. aeruginosa (90%) |
|Ceftaroline ||CAP caused by S. pneumoniae, MSSA, H. influenzae, K. pneumoniae, Klebsiella oxytoca, and E. coli; acute bacterial skin and skin-structure infections caused by MSSA, MRSA, Streptococcus pyogenes, Streptococcus agalactiae, E. coli, K. pneumoniae, and Klebsiella oxytoca ||Mostly susceptible; four strains of MRSA with ceftaroline MICs >4 μg/mL reported in isolates from a single Greek hospitale |
|Ceftazidime-avibactam, meropenem-vaborbactam ||Complicated UTIs (ceftazidime-avibactam and meropenem-vaborbactam) and complicated intraabdominal infections (ceftazidime-avibactam in combination with metronidazole) caused by resistant gram-negative organisms, including Pseudomonas, and some anaerobes || |
P. aeruginosa (84–97%)f
MDR Enterobacteriaceae, including carbapenem-resistant Enterobacteriaceae that produce KPCs
No activity against metallo-β-lactamases (e.g., NDM)
|Ceftolozane-tazobactam ||Complicated UTIs and complicated intraabdominal infections (in combination with metronidazole) caused by resistant gram-negative organisms, including Pseudomonas, and some anaerobes || |
P. aeruginosa (>86% overall; 60–80% of ceftazidime- and meropenem-resistant strains)f
No activity against KPC-producing organisms
|Imipenem, meropenem ||Intraabdominal infections, infections caused by Enterobacter spp. and ESBL-producing gram-negative bacilli ||P. aeruginosa (84%); Acinetobacter calcoaceticus-baumannii complex (93%) (meropenem susceptibilities reported) |
|Ertapenem ||CAP; complicated UTIs, including pyelonephritis; acute pelvic infections; complicated intraabdominal infections; complicated skin and skin-structure infections, excluding diabetic foot infections accompanied by osteomyelitis or caused by P. aeruginosa ||Enterobacter cloacae (88%); K. pneumoniae (99%) |
|Aztreonam ||HAIs caused by facultative gram-negative bacilli and Pseudomonas in penicillin-allergic patients ||P. aeruginosa (74%) |
|Vancomycin ||Bacteremia, endocarditis, and other invasive disease caused by MRSA; pneumococcal meningitis; oral formulation for CDAD ||S. aureus (100%); E. faecalis (96%); E. faecium (33%) |
|Telavancin ||Hospital- and ventilator-associated pneumonia or skin and soft tissue infections caused by MRSA ||S. aureus: none reported |
|Dalbavancin, oritavancin ||Complicated skin and soft tissue infections ||S. aureus: rarely reported for dalbavancin,g none reported for oritavancin |
|Daptomycin ||VRE infections; MRSA bacteremia ||E. faecalis (99.9%);h E. faecium (99.7%);h S. aureus (99.9%)g |
|Gentamicin, tobramycin, amikacin ||Combined with penicillin for staphylococcal, enterococcal, or streptococcal endocarditis; combined with β-lactam for gram-negative bacteremia; pyelonephritis ||E. coli (gentamicin, 90%); P. aeruginosa (amikacin, 91%; gentamicin, 87%); A. calcoaceticus-baumannii complex (gentamicin, 94%) |
|Azithromycin, clarithromycin, erythromycin ||Legionella, Campylobacter, and Mycoplasma infections; CAP; GAS pharyngitis in penicillin-allergic patients; bacillary angiomatosis; gastric infections due to Helicobacter pylori; MAI infections ||S. pneumoniae (60%); group A streptococci (82%); H. pylori (75%)i |
|Clindamycin ||Severe, invasive GAS infections (with β-lactam); infections caused by obligate anaerobes; infections caused by susceptible staphylococci ||S. aureus (69%) |
|Doxycycline, minocycline ||Acute bacterial exacerbations of chronic bronchitis; granuloma inguinale; brucellosis (with streptomycin); tularemia; glanders; melioidosis; spirochetal infections caused by Borrelia (Lyme disease and relapsing fever; doxycycline); infections caused by Vibrio vulnificus; some Aeromonas infections; infections due to Stenotrophomonas (minocycline); plague; ehrlichiosis; chlamydial infections (doxycycline); granulomatous infections due to Mycobacterium marinum (minocycline); rickettsial infections; mild CAP; skin and soft tissue infections caused by gram-positive cocci (e.g., CA-MRSA infections); leptospirosis; syphilis; and actinomycosis in the penicillin-allergic patient ||S. pneumoniae (68%); S. aureus (94%) |
|Tigecycline ||CAP caused by S. pneumoniae, H. influenzae, or Legionella pneumophila; complicated skin infections caused by E. coli, MRSA, MSSA, S. pyogenes, Streptococcus anginosus, S. agalactiae, B. fragilis; complicated intraabdominal infections caused by E. coli, vancomycin-susceptible E. faecalis, Citrobacter freundii, Enterobacter cloacae, K. pneumoniae, K. oxytoca, Bacteroides spp., Clostridium perfringens, and Peptostreptococcus spp. ||Mostly susceptible, although case reports of resistance in A. baumannii and K. pneumoniae |
|TMP-SMX ||Community-acquired UTI; CA-MRSA skin and soft tissue infections ||E. coli (71%); S. aureus (95%) |
|Sulfonamides ||Nocardial infections; leprosy (dapsone); toxoplasmosis (sulfadiazine) ||Unknown |
|Ciprofloxacin, levofloxacin, moxifloxacin, delafloxacin ||CAP (levofloxacin and moxifloxacin); UTI; bacterial gastroenteritis; hospital-acquired gram-negative enteric infections; Pseudomonas infections (ciprofloxacin and levofloxacin); skin and skin-structure infections (delafloxacin) ||S. pneumoniae (99%); E. coli (80%); P. aeruginosa (ciprofloxacin, 77%; levofloxacin, 77%); Salmonella spp. (ciprofloxacin, 88%; levofloxacin, 98%) |
|Rifampin ||Staphylococcal foreign body infections (in combination with other antistaphylococcal agents); Legionella pneumonia; Mycobacterium tuberculosis; atypical nontuberculous mycobacterial infection; pneumococcal meningitis when organisms are susceptible or response is delayed ||S. aureus (99%), although staphylococci rapidly develop resistance with monotherapy |
|Metronidazole ||Obligate anaerobic gram-negative bacteria (e.g., Bacteroides spp); abscess in lung, brain, or abdomen; bacterial vaginosis; CDAD ||Mostly susceptible; resistance very rare |
|Linezolid, tedizolid ||VRE; uncomplicated and complicated skin and soft tissue infections caused by MSSA and MRSA; CAP with concurrent bacteremia; hospital-acquired pneumonia ||Mostly susceptible; resistance occasionally seen in VRE |
|Chloramphenicol ||HAI due to gram-positive and gram-negative organisms resistant to standard alternatives (e.g., Burkholderia) ||Unknown |
|Colistin ||HAI due to gram-negative bacilli resistant to all other chemotherapy (e.g., P. aeruginosa, Acinetobacter spp., and Stenotrophomonas maltophilia) ||P. aeruginosa (case reports, outbreaks) |
|Quinupristin-dalfopristin ||VRE; complicated skin and skin-structure infections due to MSSA and S. pyogenes ||E. faecalis (<20%);j E. faecium (>90%)j |
|Mupirocin ||Topical application to nares for S. aureus decolonization ||S. aureus (74–100%)k |
|Nitrofurantoin ||UTI caused by most gram-negative bacilli and some gram-positive organisms; prophylaxis in recurrent cystitis ||E. coli (95%); E. faecalis (99%) |
|Fosfomycin ||UTI caused by most gram-negative bacilli and some gram-positive organisms; prophylaxis in recurrent cystitis ||Unknown |
The β-lactam class of antibiotics consists of penicillins, cephalosporins, carbapenems, and monobactams. The term β-lactam reflects the drugs’ four-membered lactam ring, which is their core structure. The differing side chains among the agents of this family determine the spectrum of activity. All β-lactams exert a bactericidal effect by inhibiting bacterial cell-wall synthesis. The β-lactams are classified as time-dependent killing agents; therefore, their clinical efficacy is best correlated with the proportion of the dosing interval during which drug levels remain above the MIC for the pathogenic organism.
Penicillins and β-Lactamase Inhibitors
Penicillin, the first β-lactam, was discovered in 1928 by Alexander Fleming. Natural penicillins, such as penicillin G, are active against non-β-lactamase-producing gram-positive and gram-negative bacteria, anaerobes, and some gram-negative cocci. Penicillin G is used for penicillin-susceptible streptococcal infections, pneumococcal and meningococcal meningitis, enterococcal endocarditis, and syphilis. The antistaphylococcal penicillins, which have potent activity against methicillin-susceptible Staphylococcus aureus (MSSA), include nafcillin, oxacillin, dicloxacillin, and flucloxacillin. Aminopenicillins, such as ampicillin and amoxicillin, provide added coverage beyond penicillin against gram-negative cocci, such as Haemophilus influenzae, and some Enterobacteriaceae, including Escherichia coli, Proteus mirabilis, Salmonella, and Shigella. The aminopenicillins are hydrolyzed by many common β-lactamases. These drugs are commonly used for infections caused by susceptible enterococcal and streptococcal species. IV ampicillin is commonly used in meningitis and endocarditis. Oral amoxicillin may be an option for otitis media, respiratory tract infections, and urinary tract infections. The antipseudomonal penicillins include ticarcillin and piperacillin. These penicillin groups generally offer adequate anaerobic coverage; the exceptions are Bacteroides species (such as Bacteroides fragilis), which produce β-lactamases and are generally resistant. The rising prevalence of β-lactamase-producing bacteria has led to the increased use of β-lactam–β-lactamase inhibitor combinations, such as ampicillin-sulbactam, amoxicillin-clavulanate, ticarcillin-clavulanate, piperacillin-tazobactam, ceftolozane-tazobactam, ceftazidime-avibactam, and meropenem-vaborbactam. The β-lactamase inhibitors themselves do not have antibacterial activity (with the exception of sulbactam, which has activity against Acinetobacter baumannii) but typically inhibit the S. aureus class A β-lactamase, β-lactamases of H. influenzae and Bacteroides species, and a number of plasmid-encoded β-lactamases. These combination agents are typically used when broader-spectrum coverage is needed—e.g., in pneumonia and intraabdominal infections. Piperacillin-tazobactam is a useful agent for broad coverage in febrile neutropenic patients. Avibactam and vaborbactam inhibit a broader spectrum of β-lactamases than the other inhibitors, including extended-spectrum β-lactamases (ESBLs), AmpC β-lactamases, and some carbapenemases (see Chap. 140).
The cephalosporin drug class encompasses several generations determined by spectrum of antibacterial activity. The first generation (cefazolin, cefadroxil, and cephalexin) largely has activity against gram-positive bacteria, with some additional activity against E. coli, P. mirabilis, and Klebsiella pneumoniae. First-generation cephalosporins are commonly used for infections caused by MSSA and streptococci (e.g., skin and soft tissue infections). Cefazolin is a popular choice for surgical prophylaxis against skin organisms. The second generation (cefamandole, cefuroxime, cefaclor, cefprozil, cefuroxime axetil, cefoxitin, and cefotetan) has additional activity against H. influenzae and Moraxella catarrhalis. Cefoxitin and cefotetan have potent activity against anaerobes as well. Second-generation cephalosporins are used to treat community-acquired pneumonia because of their activity against S. pneumoniae, H. influenzae, and M. catarrhalis. They are also used for other mild or moderate infections, such as acute otitis media and sinusitis. The third-generation cephalosporins are characterized by greater potency against gram-negative bacilli and reduced potency against gram-positive cocci. These cephalosporins, which include cefoperazone, cefotaxime, ceftazidime, ceftriaxone, cefdinir, cefixime, and cefpodoxime, are used for infections caused by Enterobacteriaceae, although resistance is an increasing concern. Ceftriaxone penetrates the CSF and can be used to treat meningitis caused by H. influenzae, N. meningitidis, and susceptible strains of S. pneumoniae. It is also used for the treatment of later-stage Lyme disease, gonococcal infections, and streptococcal endocarditis. It is noteworthy that ceftazidime is the only third-generation cephalosporin with activity against Pseudomonas aeruginosa but lacks activity against gram-positive bacteria. This drug is frequently used for pulmonary infections in cystic fibrosis, postneurosurgical meningitis, and febrile neutropenia. The fourth generation of cephalosporins includes cefepime and cefpirome, broad-coverage agents with potent activity against both gram-negative bacilli, including P. aeruginosa, and gram-positive cocci. The fourth generation has clinical applications similar to those of the third generation and may offer additional activity over the first, second, and third generations in the presence of certain β-lactamases. These agents can be used in bacteremia, febrile neutropenia, and intraabdominal and urinary tract infections. Ceftaroline, a fifth-generation cephalosporin, differs from the other cephalosporins in its added activity against MRSA, which is resistant to all other β-lactams. Ceftaroline’s gram-negative activity is similar to that of the third-generation cephalosporins but does not include P. aeruginosa. Ceftaroline may be used in community-acquired pneumonia and skin infections, and emerging data support its use in more severe infections such as bacteremia. Adverse reactions to ceftaroline have included hypersensitivity reactions and neutropenia. Ceftolozane-tazobactam and ceftazidime-avibactam are novel cephalosporin–β-lactamase inhibitor combinations with activity against gram-negative bacteria, including Pseudomonas, and some anaerobes. Both agents have been studied in complicated intraabdominal infections and complicated urinary tract infections. Ceftolozane-tazobactam is thought to be stable against many ESBL-producing organisms because of the tazobactam component. The addition of avibactam to ceftazidime yields a combination agent with activity against AmpC-, ESBL-, and KPC-producing organisms. These cephalosporin–β-lactamase inhibitor combinations may be of clinical benefit in multidrug-resistant gram-negative infections.
Carbapenems, including doripenem, imipenem, meropenem, and ertapenem, offer the most reliable coverage for strains containing ESBLs. All carbapenems have broad activity against gram-positive cocci, gram-negative bacilli, and anaerobes. None is active against methicillin-resistant S. aureus (MRSA), but all are active against MSSA, Streptococcus species, and Enterobacteriaceae. Ertapenem is the only carbapenem that has poor activity against P. aeruginosa and Acinetobacter. Imipenem is active against penicillin-susceptible Enterococcus faecalis but not Enterococcus faecium. Carbapenems are not active against Enterobacteriaceae containing carbapenemases. Stenotrophomonas maltophilia and some Bacillus species are intrinsically resistant to carbapenems because of a zinc-dependent carbapenemase. Addition of vaborbactam to meropenem results in inhibition of AmpC β-lactamases, ESBLs, and K. pneumoniae carbapenemases (KPCs).
Aztreonam is the sole monobactam. Its activity is limited to gram-negative bacteria and includes P. aeruginosa and most other Enterobacteriaceae. This drug is inactivated by ESBLs and carbapenemases. The principal use for aztreonam is as an alternative to penicillins, cephalosporins, or carbapenems in patients with a serious β-lactam allergy. Aztreonam is structurally related to ceftazidime and should be used cautiously in individuals with a serious ceftazidime allergy. It is commonly used in febrile neutropenia and intraabdominal infections.
Adverse Reactions to β-Lactam Drugs
Agents within the β-lactam class are known for several adverse effects. Gastrointestinal side effects, mainly diarrhea, are common, but hypersensitivity reactions constitute the most common adverse effect of β-lactams. The reactions’ severity can range from rash to anaphylaxis, but the rate of true anaphylactic reactions is only 0.05%. An individual with an accelerated IgE-mediated reaction to one β-lactam agent may still receive another agent within the class, but caution should be used in choosing a β-lactam that has a dissimilar side chain and a low level of cross-reactivity. For example, the second-, third-, and fourth-generation cephalosporins and the carbapenems display very low cross-reactivity in patients with penicillin allergy. Aztreonam is the only β-lactam that has no cross-reactivity with the penicillin group. In cases of severe allergy, desensitization (a graded challenge) to the indicated β-lactam, with close monitoring, may be warranted if other antibacterial options are not suitable.
β-Lactams can rarely cause serum sickness, Stevens-Johnson syndrome, nephropathy, hematologic reactions, and neurotoxicity. Neutropenia appears to be related to high doses or prolonged use. Neutropenia and interstitial nephritis caused by β-lactams generally resolve upon discontinuation of the agent. Imipenem and cefepime are associated with an increased risk of seizure, but this risk is likely a class effect and related to high doses or doses that are not adjusted in renal impairment.
GLYCOPEPTIDES AND LIPOGLYCOPEPTIDES
Vancomycin is a glycopeptide antibiotic with activity against staphylococci (including MRSA and coagulase-negative staphylococci), streptococci (including S. pneumoniae), and enterococci. It is not active against gram-negative organisms. Vancomycin also displays activity against Bacillus species, Corynebacterium jeikeium, Listeria monocytogenes, and gram-positive anaerobes such as Peptostreptococcus, Actinomyces, Clostridium, and Propionibacterium species. Vancomycin has several important clinical uses. It is used for serious infections caused by MRSA, including health care–associated pneumonia, bacteremia, osteomyelitis, and endocarditis. It is also commonly used for skin and soft tissue infections. Oral vancomycin is not absorbed systemically and is reserved for the treatment of Clostridium difficile infection. Vancomycin is also an alternative for the treatment of infections caused by MSSA in patients who cannot tolerate β-lactams. Resistance to vancomycin is a rising concern. Strains of vancomycin-intermediate S. aureus (VISA) and vancomycin-resistant enterococci (VRE) are not uncommon. Vancomycin appears to be a concentration-dependent killer, with the AUC/MIC ratio being the best predictor of efficacy (Fig. 139-2). Guidelines recommend targeting a vancomycin trough level of 15–20 μg/mL in MRSA infections in order to maintain an AUC/MIC ratio >400. When using vancomycin, clinicians should monitor for nephrotoxicity. The risk increases when trough levels are >20 μg/mL. Concomitant therapy with other nephrotoxic agents, such as aminoglycosides, also increases the risk of nephrotoxicity. Ototoxicity was reported with early formulations of vancomycin but is currently uncommon because purer formulations are available. Both of these adverse effects are reversible upon discontinuation of vancomycin. Clinicians should be aware of the “red man syndrome,” a common reaction that presents as a rapid onset of erythematous rash or pruritus on the head, face, neck, and upper trunk. This reaction is caused by histamine release from basophils and mast cells and can be treated with diphenhydramine and slowing of the vancomycin infusion.
Telavancin, dalbavancin, and oritavancin are structurally similar to vancomycin and are referred to as lipoglycopeptides. They have antibacterial activity against S. aureus (including MRSA and some strains of VISA and vancomycin-resistant S. aureus [VRSA]), streptococci, and enterococci. Oritavancin may have activity against some strains of VRE. These lipoglycopeptide agents also provide coverage against anaerobic gram-positive organisms except for Lactobacillus and some Clostridium species. The clinical efficacy of telavancin has been demonstrated in both skin and soft tissue infections and nosocomial pneumonia, and the efficacy of dalbavancin and oritavancin has been shown in skin and soft tissue infections. The vancomycin resistance phenotype may reduce the potency of all three lipoglycopeptides, but the rate of resistance to these drugs among S. aureus and enterococcal isolates has been low. Adverse effects of telavancin include nephrotoxicity, metallic taste, and gastrointestinal side effects. Clinicians should be aware of the potential for electrocardiographic QTc prolongation that can increase the risk of cardiac arrhythmias when telavancin is used concomitantly with other QTc-prolonging agents. Telavancin may interfere with certain coagulation tests (e.g., causing false elevations in prothrombin time). Dalbavancin and oritavancin have safety profiles similar to that of vancomycin, with common effects reported as headache and gastrointestinal side effects. These glycolipopeptides should be used cautiously in patients with hypersensitivity reactions to vancomycin, as cross-allergy may be possible.
Daptomycin is a lipopeptide antibiotic with activity against a broad range of gram-positive organisms. This drug is active against staphylococci (including MRSA and coagulase-negative staphylococci), streptococci, and enterococci. Daptomycin remains active against enterococci that are resistant to vancomycin. In addition, it exhibits activity against Bacillus, Corynebacterium, Peptostreptococcus, and Clostridium species. Daptomycin’s pharmacodynamic parameter for efficacy is concentration-dependent killing. Resistance to daptomycin is rare, but MICs may be higher for VISA strains. Daptomycin can be used in skin and soft tissue infections, bacteremia, endocarditis, and osteomyelitis. It is an important alternative for MRSA and other gram-positive infections when bactericidal therapy is needed and vancomycin cannot be used. Daptomycin is generally well tolerated, and its main toxicity consists of elevation of creatine phosphokinase (CPK) levels and myopathy. CPK should be monitored during daptomycin treatment, and the drug should be discontinued if muscular toxicities occur. There have also been case reports of reversible eosinophilic pneumonia associated with daptomycin use.
The aminoglycosides are a class of antibacterial agents with concentration-dependent activity against most gram-negative organisms. The most commonly used aminoglycosides are gentamicin, tobramycin, and amikacin, although others, such as streptomycin, kanamycin, neomycin, and paromomycin, may be used in special circumstances. Aminoglycosides have a significant dose-dependent postantibiotic effect; i.e., they have an antibacterial effect even after serum drug levels are undetectable. The postantibiotic effect and concentration-dependent killing form the rationale behind extended-interval aminoglycoside dosing, in which a larger dose is given once daily rather than smaller doses multiple times daily. Aminoglycosides are active against gram-negative bacilli, such as Enterobacteriaceae, P. aeruginosa, and Acinetobacter. They also enhance the activity of cell wall–active agents such as β-lactams or vancomycin against some gram-positive bacteria, including staphylococci and enterococci. This combination therapy is termed synergistic because the effect of both agents provides a killing effect greater than would be predicted from the effects of either agent alone. Amikacin and streptomycin have activity against Mycobacterium tuberculosis, and amikacin has activity against Mycobacterium avium-intracellulare. The aminoglycosides do not have activity against anaerobes, S. maltophilia, or Burkholderia cepacia. Aminoglycosides are used in clinical practice in a variety of infections caused by gram-negative organisms, including bacteremia and urinary tract infections. They are frequently used alone or in combination for the treatment of P. aeruginosa infection. When used in combination with a cell wall–active agent, gentamicin and streptomycin are also important for the treatment of gram-positive bacterial endocarditis. All aminoglycosides can cause nephrotoxicity and ototoxicity. The risk of nephrotoxicity is not well defined; however, some studies have indicated that the effect may be related to the duration of therapy as well as to the concomitant use of other nephrotoxic agents. Nephrotoxicity is usually reversible, but ototoxicity can be irreversible.
The macrolides (azithromycin, clarithromycin, and erythromycin) and ketolides (telithromycin) are classes of antibiotics that inhibit protein synthesis. Compared with erythromycin (the older antibiotic), azithromycin and clarithromycin have better oral absorption and tolerability. Azithromycin, clarithromycin, and telithromycin all have broader spectra of activity than erythromycin, which is less frequently used. These agents are commonly used in the treatment of upper and lower respiratory tract infections caused by S. pneumoniae, H. influenzae, M. catarrhalis, and atypical organisms (e.g., Chlamydia pneumoniae, Legionella pneumophila, and Mycoplasma pneumoniae); group A streptococcal pharyngitis in penicillin-allergic patients; and nontuberculous mycobacterial infections (e.g., caused by Mycobacterium marinum and Mycobacterium chelonae) as well as in the prophylaxis and treatment of M. avium-intracellulare infection in patients with HIV/AIDS and in combination therapy for Helicobacter pylori infection and bartonellosis. Enterobacteriaceae, Pseudomonas species, and Acinetobacter species are intrinsically resistant to macrolides as a result of decreased membrane permeability, although azithromycin is active against gram-negative diarrheal pathogens. The major adverse effects of this drug class include nausea, vomiting, diarrhea and abdominal pain, prolongation of QTc interval, exacerbation of myasthenia gravis, and tinnitus. Azithromycin specifically has been associated with an increased risk of death, especially among patients with underlying heart disease, because of the risk of QTc interval prolongation and torsades de pointes. Erythromycin, clarithromycin, and telithromycin inhibit the CYP3A4 hepatic drug-metabolizing enzyme and can result in increased levels of coadministered drugs, including benzodiazepines, statins, warfarin, cyclosporine, and tacrolimus. Azithromycin does not inhibit CYP3A4 and therefore does not interact with these drugs.
Clindamycin is a lincosamide antibiotic and is bacteriostatic against some organisms and bactericidal against others. It is used most often to treat bacterial infections caused by anaerobes (e.g., B. fragilis, Clostridium perfringens, Fusobacterium species, Prevotella melaninogenicus, and Peptostreptococcus species) and susceptible staphylococci and streptococci. Clindamycin is used for treatment of dental infections, anaerobic lung abscess, and skin and soft tissue infections. It is used together with bactericidal agents (penicillins or vancomycin) to inhibit new toxin synthesis in the treatment of streptococcal or staphylococcal toxic shock syndrome. Other uses include treatment of infections caused by Capnocytophaga canimorsus, combination therapy for malaria and babesiosis, and therapy for toxoplasmosis. Clindamycin has excellent oral bioavailability. Adverse effects include nausea, vomiting, diarrhea, C. difficile–associated diarrhea and pseudomembranous colitis, maculopapular rash, and (rarely) Stevens-Johnson syndrome.
TETRACYCLINES AND GLYCYLCYCLINES
The tetracyclines (doxycycline, minocycline, and tetracycline) and the glycylcyclines (tigecycline) inhibit protein synthesis and are bacteriostatic. These drugs have wide clinical uses. They are used in the treatment of skin and soft tissue infections caused by gram-positive cocci (including MRSA), spirochetal infections (e.g., Lyme disease, syphilis, leptospirosis, and relapsing fever), rickettsial infections (e.g., Rocky Mountain spotted fever), atypical pneumonia, sexually transmitted infections (e.g., Chlamydia trachomatis infection, lymphogranuloma venereum, and granuloma inguinale), infections with Nocardia and Actinomyces, brucellosis, tularemia, Whipple’s disease, and malaria. Tigecycline, the only approved agent in the glycylcycline class, is a derivative of minocycline and is indicated in the treatment of complicated skin and soft tissue infections, complicated intraabdominal infections, and community-acquired bacterial pneumonia in adults. Tigecycline has activity against MRSA, vancomycin-sensitive enterococci, many Enterobacteriaceae, and Bacteroides species; it has no activity against P. aeruginosa. This drug has been used in combination with colistin for the treatment of serious infections with multidrug-resistant gram-negative organisms. A pooled analysis of 13 clinical trials found an increased risk of death and treatment failure among patients given tigecycline alone; as a result, the U.S. Food and Drug Administration mandated a black box warning. Tetracyclines have reduced absorption when orally coadministered with calcium- and iron-containing compounds, including milk, and doses should be spaced at least 2 h apart. The major adverse reactions to both of these classes are nausea, vomiting, diarrhea, and photosensitivity. Tetracyclines have been associated with fetal bone-growth abnormalities and should be avoided during pregnancy and in the treatment of children <8 years old.
Trimethoprim-sulfamethoxazole (TMP-SMX) is an antibiotic with two components that inhibit folate synthesis and produce antibacterial activity. TMP-SMX is active against gram-positive bacteria such as staphylococci and streptococci; however, its use against MRSA is usually limited to community-acquired infections, and its activity against Streptococcus pyogenes may not be reliable. This drug is also active against many gram-negative bacteria, including H. influenzae, E. coli, P. mirabilis, Neisseria gonorrhoeae, and S. maltophilia. TMP-SMX is not active against anaerobes or P. aeruginosa. It has many uses because of its wide spectrum of activity and high oral bioavailability. Urinary tract infections, skin and soft tissue infections, and respiratory tract infections are among the common uses. Another important indication is for both prophylaxis and treatment of Pneumocystis jirovecii infections in immunocompromised patients. Resistance to TMP-SMX has limited its use against many Enterobacteriaceae. Resistance rates among urinary isolates of E. coli are almost 25% in the United States. The most common adverse reactions associated with TMP-SMX are gastrointestinal effects such as nausea, vomiting, and diarrhea. In addition, rash is a common allergic reaction and may preclude the subsequent use of other sulfonamides. With prolonged use, leukopenia, thrombocytopenia, and granulocytopenia can develop. TMP-SMX can also cause nephrotoxicity, hyperkalemia, and hyponatremia, which are more common at high doses. TMP-SMX has several important interactions with other drugs (Table 139-4), including warfarin, phenytoin, and methotrexate.
The fluoroquinolones include norfloxacin, ciprofloxacin, ofloxacin, levofloxacin, moxifloxacin, gemifloxacin, and delafloxacin. Ciprofloxacin and levofloxacin have the broadest spectrum of activity against gram-negative bacteria, including P. aeruginosa (similar to that of third-generation cephalosporins). Because of the risk of selection of resistance during fluoroquinolone treatment of serious pseudomonal infections, these agents are usually used in combination with an antipseudomonal β-lactam. Levofloxacin, moxifloxacin, gemifloxacin, and delafloxacin have additional gram-positive activity, including that against S. pneumoniae and some strains of MSSA, and, with the exception of delafloxacin, these agents are used for treatment of community-acquired pneumonia. Strains of MRSA are commonly resistant to all fluoroquinolones except delafloxacin. Moxifloxacin is used as one component of second-line regimens for multidrug-resistant tuberculosis. Fluoroquinolones exhibit concentration-dependent killing, are well absorbed orally, and have elimination half-lives that usually support once- or twice-daily dosing. Oral coadministration with compounds containing high concentrations of aluminum, magnesium, or calcium can reduce fluoroquinolone absorption. The penetration of fluoroquinolones into prostate tissue supports their use for bacterial prostatitis. Fluoroquinolones are generally well tolerated but can cause central nervous system (CNS) stimulatory effects, including seizures; peripheral neuropathy; glucose dysregulation; and tendinopathy associated with Achilles tendon rupture, particularly in older patients, organ transplant recipients, and patients taking glucocorticoids. Other potential effects on connective tissues include an association with increased risk of aortic aneurysm. Worsening of myasthenia gravis also has been associated with quinolone use. Moxifloxacin causes modest prolongation of the QTc interval and should be used with caution in patients receiving other QTc-prolonging drugs.
The rifamycins include rifampin, rifabutin, and rifapentine. Rifampin is the most commonly used rifamycin. For almost all therapeutic indications, it is used in combination with other agents to reduce the likelihood of selection of high-level rifampin resistance. Rifampin is used foremost in the treatment of mycobacterial infections—specifically, as a mainstay of combination therapy for M. tuberculosis infection or as a single agent in the treatment of latent M. tuberculosis infection. In addition, it is often used in the treatment of nontuberculous mycobacterial infection. Rifampin is used in combination regimens for the treatment of staphylococcal infections, particularly prosthetic-valve endocarditis and bone infections with retained hardware. It is a component of combination therapy for brucellosis (with doxycycline) and leprosy (with dapsone for tuberculoid leprosy and with dapsone and clofazimine for lepromatous disease). Rifampin can be used alone for prophylaxis in close contacts of patients with H. influenzae or N. meningitidis meningitis. The drug has high oral bioavailability, which is further enhanced when it is taken on an empty stomach. Rifampin has several adverse effects, including elevated aminotransferase levels (14%), rash (1–5%), and gastrointestinal events such as nausea, vomiting, and diarrhea (1–2%). Its many clinically relevant interactions with other drugs (Table 139-4) mandate the clinician’s careful review of the patient’s medications before rifampin initiation to assess safety and the need for additional monitoring, including monitoring of drug levels.
Metronidazole is used in the treatment of anaerobic bacterial infections as well as infections caused by protozoa (e.g., amebiasis, giardiasis, trichomoniasis). It is the agent of choice as a component of combination therapy for polymicrobial abscesses in the lung, brain, or abdomen, the etiology of which often includes anaerobic bacteria, and for bacterial vaginosis, pelvic inflammatory disease, and anaerobic infections, such as those due to Bacteroides, Fusobacterium, and Prevotella species. This drug is an alternative agent for treatment of mild to moderate C. difficile–associated diarrhea. Metronidazole is bactericidal against anaerobic bacteria and exhibits concentration-dependent killing. It has high oral bioavailability and tissue penetration, including penetration of the blood–brain barrier. The majority of Actinomyces, Propionibacterium, and Lactobacillus species are intrinsically resistant to metronidazole. The major adverse effects include nausea, diarrhea, and a metallic taste. Concomitant ingestion of alcohol may result in a disulfiram-like reaction, and patients are usually instructed to avoid alcohol during treatment. Long-term treatment carries the risk of leukopenia, neutropenia, peripheral neuropathy, and CNS toxicity manifesting as confusion, dysarthria, ataxia, nystagmus, and ophthalmoparesis. Through metronidazole’s effect on the CYP2C9 drug-metabolizing enzyme, its coadministration with warfarin can result in decreased metabolism and enhanced anticoagulant effects that require close monitoring. Concomitant administration of metronidazole with lithium can result in increased serum levels of lithium and associated toxicity; coadministration with phenytoin can result in phenytoin toxicity and possibly decreased levels of metronidazole.
Linezolid is a bacteriostatic agent and is indicated for serious infections due to resistant gram-positive bacteria, such as MRSA and VRE. The intrinsic resistance of gram-negative bacteria is mediated primarily by endogenous efflux pumps. Linezolid has excellent oral bioavailability. Adverse effects include myelosuppression and ocular and peripheral neuropathy with prolonged therapy. Peripheral neuropathy may be irreversible. Linezolid is a weak, reversible monoamine oxidase inhibitor, and coadministration with sympathomimetics and foods rich in tyramine should be avoided. Linezolid has been associated with serotonin syndrome when coadministered with selective serotonin-reuptake inhibitors. Tedizolid has properties similar to those of linezolid, but with lower dosing it may be less likely to cause adverse hematologic and neuropathic effects.
Nitrofurantoin’s antibacterial activity results from the drug’s conversion to highly reactive intermediates that can damage DNA and other macromolecules. Nitrofurantoin is bactericidal, and its action is concentration dependent. It displays activity against a range of gram-positive bacteria, including S. aureus, Staphylococcus epidermidis, Staphylococcus saprophyticus, E. faecalis, Streptococcus agalactiae, group D streptococci, viridans streptococci, and corynebacteria, as well as gram-negative organisms, including E. coli and Enterobacter, Neisseria, Salmonella, and Shigella species. Nitrofurantoin is used primarily in the treatment of urinary tract infections and is preferred in the treatment of such infections in pregnancy. It may be used for the prevention of recurrent cystitis. Recently, there has been interest in the use of nitrofurantoin for treatment of urinary tract infections caused by ESBL-producing Enterobacteriaceae such as E. coli, although resistance has been growing in Latin America and parts of Europe. Coadministration with magnesium should be avoided because of decreased absorption, and patients should be encouraged to take the drug with food to increase its bioavailability and decrease the risk of adverse effects, which include nausea, vomiting, and diarrhea. Nitrofurantoin may also cause pulmonary fibrosis and drug-induced hepatitis. Because the risk of adverse reactions increases with age, the use of nitrofurantoin in elderly patients is not recommended. Patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency are at elevated risk for nitrofurantoin-associated hemolytic anemia.
Colistin and polymyxin B act by disrupting bacterial cell membrane integrity and are active against the nonenteric pathogens P. aeruginosa and A. baumannii but not against Burkholderia. These drugs also exhibit activity against many Enterobacteriaceae, with the exceptions of Proteus, Providencia, and Serratia species. They lack activity against gram-positive bacteria. Polymyxins are bactericidal and are available in IV formulations. Colistimethate is converted to the active form (colistin) in plasma. Polymyxins are most often used for infections due to pathogens resistant to multiple other antibacterial agents, including urinary tract infections, hospital-acquired pneumonia, and bloodstream infections. Nebulized formulations have been used for adjunctive treatment of refractory ventilator-associated pneumonia. The most important adverse effect is dose-dependent reversible nephrotoxicity. Neurotoxicity, including paresthesias, muscle weakness, and confusion, is reversible and less common than nephrotoxicity.
Quinupristin-dalfopristin is a member of the streptogramin class of antibiotics and kills bacteria by inhibiting protein synthesis. The antibacterial spectrum of quinupristin-dalfopristin includes staphylococci (including MRSA), streptococci, and E. faecium (but not E. faecalis). This drug is also active against Corynebacterium species and L. monocytogenes. Quinupristin-dalfopristin is not reliably active against gram-negative organisms. It exhibits concentration-dependent killing, with an AUC/MIC ratio predicting efficacy. The clinical use of quinupristin-dalfopristin is largely for infections due to vancomycin-resistant E. faecium and other gram-positive bacterial infections. The drug has demonstrated efficacy in a variety of infections, including urinary tract infections, bone and joint infections, and bacteremia. Adverse effects associated with quinupristin-dalfopristin include infusion-related reactions, arthralgias, and myalgias. The arthralgias and myalgias may be severe enough to warrant drug discontinuation. Quinupristin-dalfopristin inhibits the CYP3A4 drug-metabolizing enzyme, with consequent drug interactions (Table 139-4).
Fosfomycin is a phosphonic acid antibiotic that has greater activity in acidic environments and is excreted in its active form in the urine. Thus, its use is primarily for prophylaxis and treatment of uncomplicated cystitis and should be avoided if there is concern about pyelonephritis. The drug is administered as a single 3-g dose that results in high urine concentrations for up to 48 h. Fosfomycin is active against S. aureus, vancomycin-susceptible enterococci and VRE, and a wide range of gram-negative organisms, including E. coli, Enterobacter species, Serratia marcescens, P. aeruginosa, and K. pneumoniae. Notably, the vast majority of ESBL-producing Enterobacteriaceae are susceptible to fosfomycin. A. baumannii and Burkholderia species are resistant. The emergence of resistance to fosfomycin has not been observed during treatment of cystitis but has been documented during treatment of respiratory tract infections and osteomyelitis. The few adverse effects that have been reported include nausea and diarrhea.
The use of chloramphenicol is limited by its potentially serious toxicities. When other agents are contraindicated or ineffective, chloramphenicol represents an alternative treatment for infections, including meningitis caused by susceptible bacteria such as N. meningitidis, H. influenzae, and S. pneumoniae. It has also been used for the treatment of anthrax, brucellosis, Burkholderia infections, chlamydial infections, clostridial infections, erlichiosis, rickettsial infections, and typhoid fever. Adverse reactions include aplastic anemia, myelosuppression, and gray baby syndrome. Chloramphenicol inhibits the CYP2C19 and CYP3A4 drug-metabolizing enzymes and consequently increases levels of many classes of drugs.
APPROACH TO PROPHYLAXIS OF INFECTION
Antibacterial prophylaxis is indicated only in selected circumstances (Table 139-6) and should be supported by well-designed studies or expert panel recommendations. In all cases, the risk or severity of the infection to be prevented should be greater than the adverse consequences of antibacterial therapy, including the potential for selection of resistance. In addition, the timing and duration of antibacterial treatment should be targeted for maximal effect and minimal required exposure. Prophylaxis of surgical-site infections targets bacteria that may contaminate the wound during the surgical procedure, including the skin flora of the patient or operating team and the air in the operating room. Delivery of the antibacterial drug within 1 h before the surgical incision is most effective. For prolonged procedures, redosing may be necessary to maintain effective blood and tissue levels until the wound is closed. Additional dosing is not recommended after the incision is closed. In patients with nasal carriage of S. aureus, preoperative decolonization with nasal mupirocin reduces the rate of S. aureus surgical-site infections and is generally recommended for high-risk procedures such as cardiac surgery and orthopedic implantation of prosthetic devices. For dental procedures, preprocedure antibacterial drugs are given to prevent transient bacteremia and the seeding of certain high-risk cardiac lesions. Prophylaxis is also used in nonprocedural settings in certain patients who have recurrent infections or who are at risk of serious infection from a specific exposure (e.g., close contact with a patient with meningococcal meningitis). Extension of prophylaxis beyond the period of infection risk (24 h in the case of surgical procedures) does not add further benefit and may increase the risk of resistance selection or C. difficile disease.
TABLE 139-6Prophylaxis of Bacterial Infections in Adults ||Download (.pdf) TABLE 139-6 Prophylaxis of Bacterial Infections in Adults
|Condition ||Antibacterial Agentsa ||Timing or Duration of Prophylaxis |
|Clean (cardiac, thoracic, neurologic, orthopedic, vascular, plastic) ||Cefazolin (vancomycin,b clindamycin) ||1 h before incision; re-dose with long procedures |
|Clean (ophthalmic) ||Topical neomycin–polymyxin B–gramicidin, topical moxifloxacin ||Every 5–15 min for 5 doses immediately prior to procedure |
|Clean-contaminated (head and neck) ||Cefazolin + metronidazole, ampicillin-sulbactamc (clindamycin) ||1 h before incision; re-dose with long procedures |
|Clean-contaminated (hysterectomy, gastroduodenal, biliary, unobstructed small intestine, urologic) ||Cefazolin, ampicillin-sulbactamc (clindamycin + aminoglycoside, aztreonam, or fluoroquinolone) ||1 h before incision; re-dose with long procedures |
|Clean-contaminated (colorectal, appendectomy) ||Cefazolin + metronidazole, ampicillin-sulbactam,c ertapenem (clindamycin + aminoglycoside, aztreonam, or fluoroquinolone) ||1 h before incision; re-dose with long procedures |
|Dirty (ruptured viscus) ||Therapeutic regimen directed at anaerobes and gram-negative bacteria (e.g., ceftriaxone + metronidazole) ||1 h before incision; re-dose with long procedures; continue for 3–5 days after procedure |
|Dirty (traumatic wound) ||Therapeutic regimen: cefazolin (clindamycin ± aminoglycoside, aztreonam, or fluoroquinolone) ||1 h before incision; re-dose with long procedures; continue for 3–5 days after procedure |
|Dental, oral, or upper respiratory procedures in patients with high-risk cardiac lesions (prosthetic valves, congenital heart defects, prior endocarditis) ||Amoxicillin PO, ampicillin IM (clindamycin PO, IV) ||Oral agents 1 h before procedure; injection 30 min before procedure |
|Recurrent S. aureus skin infectionsd ||Mupirocine ||Intranasal application for 5 days |
|Recurrent cellulitis associated with lymphatic disruptiond ||Benzathine penicillin IM monthly, oral penicillin or erythromycin twice daily ||Undefined |
|Recurrent cystitis in womend ||Nitrofurantoin, TMP-SMX, fluoroquinolone ||After sexual intercourse or 3 times weekly for up to 1 year |
|Bite wounds ||Amoxicillin-clavulanate (doxycycline, moxifloxacin) ||3–5 days |
|Recurrent spontaneous bacterial peritonitis in cirrhotic patientsd ||Fluoroquinolonef ||Undefined |
|Recurrent pneumococcal meningitis in patient with CSF leak or humoral immune defectd ||Penicillin ||Undefined |
|Exposure to patient with meningococcal meningitis ||Rifampin, ciprofloxacin ||2 days (rifampin), single dose (ciprofloxacin) |
|High-risk neutropenia (ANC, ≤100/μL for >7 days)d ||Levofloxacin or ciprofloxacinf ||Until neutropenia resolves or fever dictates use of other antibacterials |
In an era of increasing prevalence of multidrug-resistant bacteria and with a substantial amount of inappropriate antimicrobial use, the need for rational antimicrobial prescribing has never been greater (Chap. 140). Antimicrobial stewardship describes the practice of promoting the selection of the appropriate drug, dosage, route, and duration of antimicrobial therapy. Antimicrobial stewardship programs implement a variety of strategies to (1) improve patient care through appropriate antimicrobial use; (2) decrease the development of resistance within patients and populations; (3) reduce the incidence of adverse effects; and (4) control costs.
Infections caused by resistant pathogens result in significant morbidity and mortality as well as increased health care costs. Antimicrobial stewardship programs are typically multidisciplinary and often include infectious disease physicians, clinical pharmacists (usually with special training in infectious disease), clinical microbiologists, information systems specialists, infection prevention and control practitioners, and epidemiologists. These teams employ a variety of approaches to achieving the program’s goals.
Established strategies of antimicrobial stewardship programs include (1) prospective audit of antimicrobial use, with intervention and feedback; (2) formulary restriction; and (3) preauthorization. Prospective audit and feedback are usually undertaken by an infectious disease physician or a pharmacist. In this process, orders for broad-spectrum antimicrobials (e.g., carbapenems) or agents for which more cost-effective alternatives may exist (e.g., daptomycin, ceftazidime-avibactam) are reviewed on a regular basis for appropriateness. In circumstances in which an antimicrobial is used in the absence of an appropriate indication, the stewardship program team intervenes and recommends an alternative to the primary team caring for the patient. This process has been successful in several quasi-experimental studies, resulting in declines in use of broad-spectrum drugs and decreases in adverse events, such as C. difficile infection. Formulary restriction is the inclusion of a limited set of antimicrobial agents in a hospital formulary for the purpose of limiting indiscriminant use of antimicrobials in the absence of demonstrated benefit. Such restriction coincidentally serves to reduce costs. Preauthorization is the practice of requiring clinicians to obtain approval before using selected antimicrobials. Approval may be provided electronically with sophisticated Computerized Provider Order Entry (CPOE) software, after specific criteria for use are met, or after communication with an infectious disease specialist as designated by the stewardship program. These strategies have led to a decrease in C. difficile infections and to improvements in drug susceptibility patterns.
Additional strategies used in specific health care settings are guidelines and pathways, dose optimization, parenteral-to-oral conversion, antibiotic time-out, and de-escalation of therapy. Documentation of the indication for which each antimicrobial is prescribed is also encouraged. Antimicrobial stewardship is an evolving area and an increasingly active area of research aimed at identifying the best practices. The IDSA, in collaboration with several other professional organizations, has published guidelines for developing institutional antimicrobial stewardship programs (www.idsociety.org/Antimicrobial_Agents/).
et al: Implementing an antibiotic stewardship program: Guidelines by the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America. Clin Infect Dis 62:e51, 2016.
et al: Clinical practice guidelines for antimicrobial prophylaxis in surgery. Surg Infect (Larchmt) 14:73, 2013.
WA: Pharmacokinetic/pharmacodynamic parameters: Rationale for antibacterial dosing of mice and men. Clin Infect Dis 26:1, 1998.
et al (eds): Kucers’ The Use of Antibiotics. A Clinical Review of Antibacterial, Antifungal, Antiparasitic and Antiviral Drugs, 6th ed. London, Hodder Arnold, 2010.
et al: Consequences of avoiding β-lactams in patients with β-lactam allergies. J Allergy Clin Immunol 137:1148, 2016.
et al: Recent updates on the role of pharmacokinetics–pharmacodynamics in antimicrobial susceptibility testing as applied to clinical practice. Clin Infect Dis 61:1446, 2015.
et al: A multicenter evaluation of prolonged empiric antibiotic therapy in adult ICUs in the United States. Crit Care Med 43:2527, 2015.